Last year 10, CDC data showed that the effective rate of Johnson & Johnson vaccine against coronavirus pneumonia-19 was only 7 1%, while the effective rate of Pfizer vaccine was 88% and that of Moderna vaccine was 93%.
According to the US Centers for Disease Control and Prevention, the number of cases caused by Omicron mutants has increased dramatically. During the week of 65438+202210.8, Johnson & Johnson Company (J&; J) The mortality rate associated with coronavirus pneumonia among injecting drug users exceeds 65,438+5/100,000. In contrast, about 2 out of every 654.38 million people who received Pfizer or Moderna vaccine died.
The US Centers for Disease Control and Prevention also mentioned that Pfizer mRNA vaccine and Moderna mRNA vaccine are the first choice for vaccination. In some cases, Johnson's adenovirus vector vaccine can be inoculated.
Compared with the unvaccinated Americans, the use of Johnson & Johnson vaccine still reduces the mortality rate in COVID-19, and the unvaccinated mortality rate is close to 20 per 654.38+ 10,000 people.
It is reported that the mortality rate of coronavirus pneumonia-19 in people receiving intensive injection is higher than that in people receiving Pfizer or Moderna vaccine.
However, according to the data released by the US Centers for Disease Control and Prevention, the breakthrough infection rate of Johnson & Johnson vaccinators is similar to or lower than others, because federal officials are considering a new round of booster injections.
Jake Sargent, a spokesman for Johnson & Johnson Company, said: "CDC has increased more and more evidence that Johnson & Johnson coronavirus pneumonia-19 vaccine provides lasting protection for breakthrough infections and hospitalization."
However, these data are not adjusted for many factors that may affect the direct comparison between different vaccinated people, including the length of time after vaccination and potential health problems.
Dr Dan baruch, director of the Center for Virology and Vaccine Research at Beth israel Deaconess Medical Center, said in an interview: "The difference of Johnson & Johnson vaccine is that the initial antibody response is much lower than that of mRNA vaccine. But with the passage of time, these reactions have actually maintained well and even increased slightly. "
At present, only immunocompromised Johnson & Johnson injections are eligible for the third injection. But this situation may change soon. Moderna and Pfizer are both seeking to introduce additional booster injections, including recipients of Johnson & Johnson vaccine.
Dr. Anthony Fauci, the president's chief medical adviser, told reporters in 1 month: "In view of the parallel protection we have seen in Johnson & Johnson, the protection has been upgraded or the mRNA has been upgraded, and the mixing and matching have been completed. You can vaccinate on one platform and upgrade on another platform, and we find it very effective."